Northwestern Medicine shared results from a first-in-human clinical trial for a skull-implantable ultrasound device that supports chemotherapy delivery. The device opened the blood-brain barrier to repeatedly permeate large, critical regions of the human brain. This enabled the delivery of chemotherapy injected intravenously. With the patient awake, a four-minute procedure opens the blood-brain barrier and patients […]
Oncology
Researchers use tiny drug delivery implant to treat tumors
Researchers at Houston Methodist Research Institute developed a tiny drug delivery device for addressing difficult-to-treat cancers. The researchers published their work in a paper in Advanced Science. They used an implantable nanofluidic device they invented to deliver CD40 monoclonal antibodies (mAB). The team calls the device a nanofluidic drug-eluting seed (NDES). With the device — […]
Medtech veteran Tatyana Beldock joins Dyve Biosciences board
Dyve Biosciences announced today that Tatyana Beldock joined the company’s board of directors. Camarillo, California-based Dyve develops the DMAX delivery platform. Its transdermal drug delivery technology directly targets the acidic microenvironments that drive cancer cell growth and inflammation. “We are thrilled to have Tatyana join our board,” said Dr. Ryan Beal, CEO of Dyve. “Tatyana brings […]
Study supports RenovoRx drug-device combo for treating pancreatic cancer
RenovoRx (Nasdaq:RNXT) today announced promising interim data for its RenovoGem drug-device combination for treating pancreatic cancer. The Tiger-Pac clinical trial investigates RenovoGem as a potential treatment option in locally advanced pancreatic cancer (LAPC). Interim data from the Phase III open-label study suggests a six-month potential improvement in median overall survival with RenovoGem. RenovoGem utilizes the […]
Bionaut Labs closes $43M Series B for robotic drug delivery tech
Robotic drug delivery technology developer Bionaut Labs announced today that it closed a Series B financing round worth $43.2 million. Los Angeles-based Bionaut Labs uses microscale robots to deliver drugs for treating central nervous system (CNS) diseases and disorders. Through magnetic propulsion, the company’s Bionauts can navigate the human body and deliver drugs locally. The […]
TriSalus releases positive data for its catheter-based drug delivery tech
TriSalus Life Sciences today announced positive clinical results for its Pressure-Enabled Regional Immuno-Oncology technology. The company, currently in the process of going public through a SPAC merger, filed a presentation for investors. It features information regarding its ongoing PERIO 01 and PERIO 02 clinical studies. The studies evaluate the TriNav pressure-enabled drug delivery technology for […]
FDA approves Medtronic drug-eluting stents for treating bifurcation lesions
Medtronic (NYSE:MDT) announced today that the FDA approved its Onyx drug-eluting stents (DES) for treating certain lesions. Approval covers the treatment of non-left main bifurcation lesions utilizing the provisional bifurcation stenting technique. The technique uses a single stent to treat the bifurcation in percutaneous coronary interventions (PCIs). It applies to the FDA-approved and CE-marked Onyx […]
FDA clears embolic microspheres from ABK Biomedical
ABK Biomedical announced today that it received FDA 510(k) clearance for its Easi-Vue embolic microspheres for treating tumors. Halifax, Nova Scotia-based ABK designed its microspheres for treating patients with arteriovenous malformations and hypervascular tumors. Vascular embolization is an effective therapy for addressing symptoms of these conditions. ABK said in a news release that microsphere embolization […]
Study backs Fluidx embolic device for vessel filling
Fluidx Medical announced today that study results support vessel filling with its GPX embolic device when compared to microspheres. Salt Lake City-based Fluidx designed the GPX embolic device for simple preparation and controllable material delivery, packaged ready-to-use in a syringe and capable of being prepped tableside by a clinician in about 30 seconds. It may […]
FDA approves first targeted infusion therapy for HER2-low breast cancer
The FDA announced today that it approved Enhertu, an IV infusion for the treatment of patients with unresectable or metastatic HER2-low breast cancer. Enhertu (fam-trastuzumab-deruxtecan-nxki) IV infusion is now the first approved therapy targeted to patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer. The therapy received […]
